GET DAILY SIGNALSLongeveron (LGVN) Q3 2026 Earnings: Pipeline Progress and Cash Runway in Focus
Key Takeaways
- Longeveron Inc. (LGVN) is expected to report its third-quarter 2026 results in early November 2026, after the U.S. market close, followed by a conference call.
- Wall Street consensus points to a net loss near $1.95 per share on revenue of approximately $0.56 million, a sharp improvement from a loss of $3.90 per share on $0.14 million in revenue a year earlier.
- As a clinical-stage biotechnology company, Longeveron’s quarterly revenue remains modest, so investors are focused on pipeline progress and cash position rather than top-line growth.
- The key catalyst is the ELPIS II Phase 2b trial of Lomecel-B (laromestrocel) in hypoplastic left heart syndrome (HLHS), a rare and life-threatening congenital heart condition.
- Cash runway is a central concern: management previously indicated existing cash could fund operations into the fourth quarter of 2026, making financing updates highly relevant.
Putting the Earnings Release in Context
Longeveron is developing Lomecel-B, a cellular therapy targeting aging-related conditions and rare pediatric diseases, most notably HLHS. Because the company is pre-commercial, its quarterly earnings serve less as a measure of profitability and more as a barometer of cash burn, trial execution, and timeline credibility. In the second quarter of 2026, Longeveron reported revenue of about $0.29 million and a net loss of $6.1 million, with roughly $10.1 million in cash at quarter-end. With a key clinical data readout anticipated around this period, the upcoming report and accompanying business update are critical for gauging whether the company can reach its next value-driving milestone without significant dilution.
What Analysts Are Projecting
Analysts expect Longeveron to post a narrower year-over-year loss for the third quarter of 2026. Consensus estimates call for earnings per share (EPS) of approximately -$1.95, compared with a reported loss of $3.90 per share in the third quarter of 2025. Revenue is forecast to reach roughly $0.56 million, up from about $0.14 million in the prior-year period, driven primarily by clinical trial revenue. Investors will also watch research and development (R&D) and general and administrative (G&A) spending, which management has been working to control. Given the company’s cash position, commentary on financing plans, non-dilutive funding, and the timing of the ELPIS II data readout will likely matter more to the stock than the headline EPS figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Sentiment heading into the report is shaped by anticipation of the ELPIS II clinical data rather than the quarterly financials alone. Longeveron shares have been volatile, reflecting the high-risk, high-reward profile typical of clinical-stage biotechs awaiting a pivotal readout. Historically, the stock has reacted more to trial and financing news than to modest revenue changes. Key risk factors include a potential delay in the data readout, a larger-than-expected cash burn, or dilutive financing. Conversely, any confirmation of timeline progress or favorable early signals could support a positive reaction. Investors should expect above-average volatility around the announcement.
Forward Outlook and Key Factors to Monitor
Following the third-quarter report, the single most important item to monitor is the ELPIS II Phase 2b readout for Lomecel-B in HLHS. Management has repeatedly guided toward a data release around the late-summer to early-fall 2026 window, and confirmation of that timeline will be closely watched.
Cash runway is a parallel concern. With roughly $10.1 million in cash as of June 30, 2026, and operating costs expected to remain substantial, investors will look for clarity on how the company plans to fund itself into and beyond the fourth quarter of 2026. Any mention of additional capital raises, grants, or non-dilutive funding will carry weight.
Finally, watch expense trends and trial enrollment updates. Continued cost discipline in R&D and G&A would support the company’s ability to extend its runway, while broader pipeline progress beyond HLHS could provide additional long-term optionality. As always, these developments should be considered alongside the inherent uncertainty of clinical-stage investing.
Incorporating AI Tools in My Research Process
When analyzing names like LGVN, I frequently use Tickeron’s AI Screener to filter biotech peers by technical patterns, fundamentals, and volatility metrics. This helps surface comparable trade ideas and benchmark the company’s profile against the broader sector without manual effort. The tool has become a regular part of my workflow for quickly identifying relevant opportunities in a fast-moving space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LGVN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LGVN turned positive on September 30, 2026. Looking at past instances where LGVN's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LGVN's RSI Indicator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on LGVN as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +10.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGVN advanced for three days, in 175 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
LGVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for LGVN moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LGVN entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.524) is normal, around the industry mean (3.104). P/E Ratio (-0.171) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (13.587) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. LGVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LGVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement